The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Defining the clinical course of multiple sclerosis: The 2013 revisions
Open accessAbstract
Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment of clinical trials, and treatment decision-making. Standardized descriptions published in 1996 based on a survey of international MS experts provided purely clinical phenotypes based on data and consensus at that time, but imaging and biological correlates were lacking. Increased understanding of MS and its pathology, coupled with general concern that the original descriptors may not adequately reflect more recently identified clinical aspects of the disease, prompted a re-examination of MS disease phenotypes by the International Advisory Committee on Clinical Trials of MS. While imaging and biological markers that might provide objective criteria for separating clinical phenotypes are lacking, we propose refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression. Strategies for future research to better define phenotypes are also outlined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PPMS (10-15% of patients) is characterised by an insidious, slowly progressive increase in neurological disability over time, usually without relapses.2”
From Diagnosis of multiple sclerosis: progress and challenges (2017) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“At this time it is considered essential that a diagnosis of MS only be made in a patient who has symptoms suggestive of demyelination. 2”
From Diagnosis of multiple sclerosis: progress and challenges (2017) · cites this paper as [2]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Misdiagnosis of MS remains an issue in clinical practice. 8-11”
From Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria (2018) · cites this paper as [10]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
Self-citationDefining the clinical course of multiple sclerosis
LUBLIN, F. D., & Reingold, S. C. (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,762
Self-citationB-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Self-citationJacobs, L. D., Beck, R. W., Simon, J. H., Kinkel, R. P., Brownscheidle, C. M., Murray, T. J., Simonian, N. A., Slasor, P., & Sandrock, A. W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431301 · Cited by 1,485
The Immunopathology of Multiple Sclerosis: An Overview
Lassmann, H., Brück, W., & Lucchinetti, C. F. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00064.x · Cited by 1,182
Comi, G., Filippi, M., Barkhof, F., Durelli, L., Edan, G., Fernández, Ó., Hartung, H.-P., Seeldrayers, P., Sørensen, P. S., Rovaris, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04725-5 · Cited by 1,042
Self-citationProgressive multiple sclerosis: pathology and pathogenesis
Lassmann, H., van Horssen, J., & Mahad, D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.168 · Cited by 1,033
Natural history of multiple sclerosis: a unifying concept
Confavreux, C., & Vukusic, S. (2006) · Brain · doi:10.1093/brain/awl007 · Cited by 901
Kappos, L., Polman, C. H., Freedman, M. S., Edan, G., Hartung, H., Miller, D., Montalbán, X., Barkhof, F., Bauer, L., Jakobs, P., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000237641.33768.8d · Cited by 677
Self-citationIncidental MRI anomalies suggestive of multiple sclerosis: The radiologically isolated syndrome
Okuda, D. T., Mowry, E. M., Beheshtian, A., Waubant, E., Baranzini, S. E., Goodin, D. S., Hauser, S. L., & Pelletier, D. (2009) · Neurology · doi:10.1212/01.wnl.0000335764.14513.1a · Cited by 642
Self-citation
Cited by
Sorted by citations
Items 701–800 of 1,007
[18F]Florbetapir PET/MR imaging to assess demyelination in multiple sclerosis
Carotenuto, A., Giordano, B., Dervenoulas, G., Wilson, H., Veronese, M., Chappell, Z., Polychronis, S., Pagano, G., Mackewn, J. E., Turkheimer, F., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04533-y · Cited by 34
Nasi, M., Bianchini, E., Biasi, S. D., Gibellini, L., Neroni, A., Mattioli, M., Pinti, M., Iannone, A., Mattioli, A. V., Simone, A. M., et al. (2019) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2019.577107 · Cited by 31
Medina‐Polo, J., Adot, J. M., Allué, M., Arlandis, S., Blasco, P., Casanova, B., Matías‐Guiu, J., Madurga, B., Murillo, E. R. M., Müller‐Arteaga, C., et al. (2020) · Neurourology and Urodynamics · doi:10.1002/nau.24276 · Cited by 31
Ferrazzano, G., Crisafulli, S. G., Baione, V., Tartaglia, M., Cortese, A., Frontoni, M., Altieri, M., Pauri, F., Millefiorini, E., & Conte, A. (2020) · Journal of Neurology · doi:10.1007/s00415-020-09964-4 · Cited by 31
Distinctive sphingolipid patterns in chronic multiple sclerosis lesions
Podbielska, M., Szulc, Z. M., Ariga, T., Pokryszko‐Dragan, A., Fortuna, W., Bilińska, M. M., Podemski, R., Jaśkiewicz, E., Kurowska, E., Yu, R. K., et al. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra120001022 · Cited by 31
Pulido-Valdeolivas, I., Andorrà, M., Gómez‐Andrés, D., Nakamura, K., Albà-Arbalat, S., Lampert, E. J., Zubizarreta, I., Llufriú, S., Martínez‐Heras, E., Solana, E., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-70255-z · Cited by 34
Molazadeh, N., Filippatou, A. G., Vasileiou, E. S., Levy, M., & Sotirchos, E. S. (2021) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2021.577702 · Cited by 31
Therapeutic Effects of the Pilates Method in Patients with Multiple Sclerosis: A Systematic Review
Fuentes, G. R., Silveira-Pereira, L., Ferradáns-Rodríguez, P., & Campo-Prieto, P. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030683 · Cited by 38
Magnetic Resonance Imaging in Primary Progressive Multiple Sclerosis Patients
Siger, M. (2022) · Clinical Neuroradiology · doi:10.1007/s00062-022-01144-3 · Cited by 32
Basu, S., Munafo, A., Ben-Amor, A.-F., Roy, S., Girard, P., & Terranova, N. (2022) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12796 · Cited by 31
Silfverberg, T., Zjukovskaja, C., Ljungman, P. T., Nahimi, A., Ahlstrand, E., Dreimane, A., Einarsdottir, S., Fagius, J., Iacobaeus, E., Hägglund, H., et al. (2023) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2023-331864 · Cited by 32
Poon, K. W. C., Brideau, C., Klaver, R., Schenk, G. J., Geurts, J. J. G., & Stys, P. K. (2018) · Chemical Science · doi:10.1039/c7sc03992a · Cited by 31
Gavoille, A., Rollot, F., Casey, R., Kerbrat, A., Page, E. L., Bigaut, K., Mathey, G., Michel, L., Ciron, J., Ruet, A., et al. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.1961 · Cited by 33
Mazziotti, V., Crescenzo, F., Turano, E., Guandalini, M., Bertolazzo, M., Ziccardi, S., Virla, F., Camera, V., Marastoni, D., Tamanti, A., et al. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03193-6 · Cited by 31
Moccia, M., Palladino, R., Russo, C. V., Massarelli, M., Nardone, A., Triassi, M., Lugaresi, A., & Morra, V. B. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.1078789 · Cited by 30
Chou, I., Wang, H.-S., Whitehouse, W. P., & Constantinescu, C. S. (2016) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-016-0663-4 · Cited by 30
Symptomatic treatment in multiple sclerosis-interim analysis of a nationwide registry
Skierlo, S., Rommer, P. S., & Zettl, U. K. (2016) · Acta Neurologica Scandinavica · doi:10.1111/ane.12612 · Cited by 32
Krieger, S. C., & Sumowski, J. F. (2017) · Neurologic Clinics · doi:10.1016/j.ncl.2017.08.003 · Cited by 34
Granella, F., Tsantes, E., Graziuso, S., Bazzurri, V., Crisi, G., & Curti, E. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09526-3 · Cited by 31
Artificial Intelligence shaping the future of neurology practice
Vinny, P. W., Vishnu, V. Y., & Srivastava, M. V. P. (2021) · Medical Journal Armed Forces India · doi:10.1016/j.mjafi.2021.06.003 · Cited by 31
TNFα in MS and Its Animal Models: Implications for Chronic Pain in the Disease
Maguire, A. D., Bethea, J. R., & Kerr, B. J. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.780876 · Cited by 33
Progressive Multiple Sclerosis
Amezcua, L. (2022) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001157 · Cited by 34
Associations between smartphone keystroke dynamics and cognition in MS
Chen, M. H., Leow, A., Ross, M. K., DeLuca, J., Chiaravalloti, N. D., Costa, S. L., Genova, H. M., Weber, E., Hussain, F., & Demos, A. P. (2022) · Digital Health · doi:10.1177/20552076221143234 · Cited by 30
Şenol, H., Özgün, Ö., Dağ, A., Eken, A., Güner, H., Aykut, G., Topçu, G., & Şen, A. (2023) · Journal of Natural Products · doi:10.1021/acs.jnatprod.2c00798 · Cited by 30
Dimitriou, N. G., Meuth, S. G., Martínez‐Lapiscina, E. H., Albrecht, P., & Menge, T. (2023) · CNS Drugs · doi:10.1007/s40263-022-00977-3 · Cited by 31
Bayas, A., Christ, M., Faissner, S., Klehmet, J., Pul, R., Skripuletz, T., & Meuth, S. G. (2023) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864221146836 · Cited by 33
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable
Sharmin, S., Roos, I., Simpson, S., Malpas, C. B., Martínez-Sánchez, M., Özakbaş, S., Horáková, D., Havrdová, E., Patti, F., Alroughani, R., et al. (2023) · Brain · doi:10.1093/brain/awad218 · Cited by 30
Nombela-Cabrera, R., Pérez‐Nombela, S., Avendaño‐Coy, J., Comino‐Suárez, N., Arroyo-Fernández, R., Gómez‐Soriano, J., & Serrano‐Muñoz, D. (2023) · Journal of NeuroEngineering and Rehabilitation · doi:10.1186/s12984-023-01266-w · Cited by 34
Evolution of diagnostic criteria for multiple sclerosis
Przybek-Skrzypecka, J., Gniatkowska, I., Mirowska-Guzel, D. M., & Członkowska, A. (2015) · Neurologia i Neurochirurgia Polska · doi:10.1016/j.pjnns.2015.07.006 · Cited by 32
Evaluation of lithium serum level in multiple sclerosis patients: A neuroprotective element
Karimi, A., Bahrampour, K., Momeni‐Moghaddam, M. A., Asadikaram, G., Ebrahimi, G., Torkzadeh‐Mahani, M., Tarzi, M. E., & Nematollahi, M. H. (2017) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2017.08.019 · Cited by 30
Urinary Excretion of Aluminium and Silicon in Secondary Progressive Multiple Sclerosis
Jones, K., Linhart, C., Hawkins, C., & Exley, C. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.10.028 · Cited by 30
Clinical applications of ultra-high field magnetic resonance imaging in multiple sclerosis
Inglese, M., Fleysher, L., Oesingmann, N., & Petracca, M. (2018) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2018.1433033 · Cited by 31
Self-citationHaase, R., Wunderlich, M., Dillenseger, A., Kern, R., Akgün, K., & Ziemssen, T. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1437144 · Cited by 30
The Effect of Coffee and Caffeine Consumption on Patients with Multiple Sclerosis-Related Fatigue
Herden, L., & Weissert, R. (2020) · Nutrients · doi:10.3390/nu12082262 · Cited by 31
Constraint-Induced Movement Therapy
Barghi, A., Mark, V. W., & Taub, E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805298-3.00015-3 · Cited by 30
Chitnis, T., Foley, J. F., Ionete, C., Ayoubi, N. K. E., Saxena, S., Gaitan-Walsh, P., Lokhande, H. A., Paul, A., Saleh, F., Weiner, H. L., et al. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109688 · Cited by 29
de Boer, A., van den Bosch, A. M. R., Mekkes, N., Fransen, N. L., Dagkesamanskaia, E., Hoekstra, E., Hamann, J., Smolders, J., Huitinga, I., & Holtman, I. R. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02742-w · Cited by 30
NEDA treatment target? No evident disease activity as an actionable outcome in practice
Parks, N. E., Flanagan, E. P., Lucchinetti, C. F., & Wingerchuk, D. M. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.10.015 · Cited by 30
Palliative care interventions for people with multiple sclerosis
Latorraca, C. O., Martimbianco, A. L. C., Pachito, D. V., Torloni, M. R., Pacheco, R. L., Pereira, J. G., & Riera, R. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012936.pub2 · Cited by 31
Integrative analysis of Multiple Sclerosis using a systems biology approach
Cervantes-Gracia, K., & Husi, H. (2018) · Scientific Reports · doi:10.1038/s41598-018-24032-8 · Cited by 29
Plasma proteome in multiple sclerosis disease progression
Malekzadeh, A., Leurs, C. E., van Wieringen, W. N., Steenwijk, M. D., Schoonheim, M. M., Amann, M., Naegelin, Y., Kühle, J., Killestein, J., & Teunissen, C. E. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.771 · Cited by 29
Multiple sclerosis diagnosis delay and its associated factors among Iranian patients
Mobasheri, F., Jaberi, A. R., Hasanzadeh, J., & Fararouei, M. (2020) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2020.106278 · Cited by 29
Disease Progression in Multiple Sclerosis: A Literature Review Exploring Patient Perspectives
Celius, E. G., Thompson, H., Pontaga, M., Langdon, D. W., Laroni, A., Potra, S., Bharadia, T., Yeandle, D., Shanahan, J., van Galen, P., et al. (2021) · Patient Preference and Adherence · doi:10.2147/ppa.s268829 · Cited by 29
Deep Learning Corpus Callosum Segmentation as a Neurodegenerative Marker in Multiple Sclerosis
Plattén, M., Brusini, I., Andersson, O., Ouellette, R., Piehl, F., Wang, C., & Granberg, T. (2021) · Journal of Neuroimaging · doi:10.1111/jon.12838 · Cited by 29
Vidaković, M. R., Šimić, N., Poljičanin, A., Ivanišević, M. N., Jerković, A., & Đogaš, Z. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.102850 · Cited by 29
Guerrieri, S., Comı, G., & Leocani, L. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.692599 · Cited by 29
Impact of Vitamin D Supplementation on Multiple Sclerosis
Gandhi, F. R., Jhaveri, S., Avanthika, C., Singh, A., Jain, N., Gulraiz, A., Shah, P., & Nasir, F. (2021) · Cureus · doi:10.7759/cureus.18487 · Cited by 29
Oh, J., Capezzuto, L., Kriara, L., Schjodt‐Eriksen, J., van Beek, J., Bernasconi, C., Montalbán, X., Butzkueven, H., Kappos, L., Giovannoni, G., et al. (2024) · Scientific Reports · doi:10.1038/s41598-023-49299-4 · Cited by 29
Self-citationPawlak, E., Nowak, O., Karabon, L., Pokryszko‐Dragan, A., Partyka, A., Tomkiewicz, A., Ptaszkowski, J., Frydecka, I., Podemski, R., Dybko, J., et al. (2017) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2017.02.006 · Cited by 29
Bone morphogenetic proteins in multiple sclerosis: Role in neuroinflammation
Eixarch, H., Calvo‐Barreiro, L., Montalbán, X., & Espejo, C. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.02.019 · Cited by 31
Kremer, I., Evers, S., Jongen, P. J., & Hiligsmann, M. (2017) · Health Expectations · doi:10.1111/hex.12599 · Cited by 29
Keegan, B. M., Kaufmann, T. J., Weinshenker, B. G., Kantarci, O. H., Schmalstieg, W. F., Soldán, M. M. P., & Flanagan, E. P. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458518781979 · Cited by 29
Hughes, J., Jokubaitis, V., Lugaresi, A., Hupperts, R., Izquierdo, G., Prat, A., Girard, M., Duquette, P., Grand’Maison, F., Grammond, P., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.2109 · Cited by 29
Moumdjian, L., Moens, B., Vanzeir, E., Klerck, B. D., Feys, P., & Leman, M. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14023 · Cited by 32
Zabalza, A., Vera, A., Alari‐Pahissa, E., Munteis, E., Moreira, A., Yélamos, J., Llop, M., López‐Botet, M., & Rodríguez, J. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01840-2 · Cited by 30
Mediterranean-like diets in multiple sclerosis: A systematic review
Abbasi, H., Shakouri, F., Mosaddeghi-Heris, R., Gholipour-khalili, E., Jahanshahlou, F., Sanaie, S., Naseri, A., & Talebi, M. (2023) · Revue Neurologique · doi:10.1016/j.neurol.2023.07.017 · Cited by 28
Aliyu, M., Zohora, F. T., Ceylan, A., Hossain, F., Yazdani, R., & Azizi, G. (2024) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2024.2330642 · Cited by 28
Konitsioti, A., Prüß, H., Laurent, S. A., Fink, G. R., Heesen, C., & Warnke, C. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12642-4 · Cited by 28
Ladakis, D. C., Harrison, K. L., Smith, M. D., Solem, K., Gadani, S. P., Jank, L., Hwang, S. A., Farhadi, F., Dewey, B. E., Fitzgerald, K. C., et al. (2024) · Med · doi:10.1016/j.medj.2024.09.011 · Cited by 30
Self-citationZhou, W., Xia, S., Wang, C., Yang, Q., Verkhratsky, A., & Niu, J. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07893-6 · Cited by 31
The radiologically isolated syndrome
Lebrun‐Frénay, C. (2015) · Revue Neurologique · doi:10.1016/j.neurol.2015.05.001 · Cited by 34
Al‐iedani, O., Lechner‐Scott, J., Ribbons, K., & Ramadan, S. A. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0323-2 · Cited by 28
Association of body mass index with longitudinal rates of retinal atrophy in multiple sclerosis
Filippatou, A. G., Lambe, J., Sotirchos, E. S., Fitzgerald, K. C., Aston, S. A., Murphy, O. C., Pellegrini, N., Fioravante, N., Risher, H., Ogbuokiri, E., et al. (2020) · Multiple Sclerosis Journal · doi:10.1177/1352458519900942 · Cited by 29
Self-citationReynoso-Moreno, I., Tietz, S., Vallini, E., Engelhardt, B., Gertsch, J., & Chicca, A. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00214 · Cited by 28
Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis
Roos, I., Leray, E., Casey, R., Horáková, D., Havrdová, E., Izquierdo, G., Madueño, S. E., Patti, F., Edan, G., Debouverie, M., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012354 · Cited by 29
Jerković, A., Proroković, A., Matijaca, M., Vuko, J., Poljičanin, A., Mastelić, A., Katić, A. Ć., Košta, V., Kustura, L., Dolić, K., et al. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.794353 · Cited by 33
Solodka, K., Berto, M., Ferraro, D., Menozzi, C., Borsari, M., Bortolotti, C. A., Biscarini, F., & Pinti, M. (2022) · Advanced Materials Interfaces · doi:10.1002/admi.202102341 · Cited by 28
Immunopathogenesis, Diagnosis, and Treatment of Multiple Sclerosis
Pérez, C. A., Cuascut, F. X., & Hutton, G. J. (2022) · Neurologic Clinics · doi:10.1016/j.ncl.2022.05.004 · Cited by 33
Rocca, M. A., Margoni, M., Battaglini, M., Eshaghi, A., Iliff, J. J., Pagani, E., Preziosa, P., Storelli, L., Taoka, T., Valsasina, P., et al. (2023) · Radiology · doi:10.1148/radiol.221512 · Cited by 30
High prevalence and increasing incidence of multiple sclerosis in the Norwegian county of Buskerud
Simonsen, C. S., Edland, A., Berg‐Hansen, P., & Celius, E. G. (2016) · Acta Neurologica Scandinavica · doi:10.1111/ane.12615 · Cited by 28
Salehi, Z., Doosti, R., Beheshti, M., Janzamin, E., Sahraian, M. A., & Izad, M. H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159565 · Cited by 28
Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview
Angelis, F. D., Plantone, D., & Chataway, J. (2018) · CNS Drugs · doi:10.1007/s40263-018-0538-0 · Cited by 29
Ocrelizumab for the treatment of multiple sclerosis
Bigaut, K., Seze, J. D., & Collongues, N. (2018) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1561284 · Cited by 29
Monoclonal Antibodies for Multiple Sclerosis: An Update
Graf, J., Aktaş, O., Rejdak, K., & Hartung, H. (2019) · BioDrugs · doi:10.1007/s40259-018-0327-9 · Cited by 28
Bijak, M., Olejnik, A. K., Rokita, B., Morel, A., Dziedzic, A., Miller, E. D., & Saluk, J. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14244 · Cited by 28
Online psychological interventions to improve symptoms in multiple sclerosis: A systematic review
Montañés‐Masias, B., Bort‐Roig, J., Pascual, J. C., Soler, J., & Briones‐Buixassa, L. (2022) · Acta Neurologica Scandinavica · doi:10.1111/ane.13709 · Cited by 27
Effectiveness of multiple sclerosis treatment with current immunomodulatory drugs
Milo, R. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1002769 · Cited by 27
Leurs, C. E., van Kempen, Z. L. E., Dekker, I., Balk, L. J., Wattjes, M. P., Rispens, T., Uitdehaag, B. M. J., & Killestein, J. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517726381 · Cited by 27
Treatment and disease management of multiple sclerosis patients
Roman, C., & Menning, K. (2017) · Journal of the American Association of Nurse Practitioners · doi:10.1002/2327-6924.12514 · Cited by 27
Predisposing Factors for Sexual Dysfunction in Multiple Sclerosis
Altmann, P., Leutmezer, F., Leithner, K., Monschein, T., Ponleitner, M., Stattmann, M., Rommer, P. S., Zrzavy, T., Zulehner, G., Berek, K., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.618370 · Cited by 27
Espiritu, A. I., & Remalante-Rayco, P. P. M. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103159 · Cited by 27
Hecker, M., Frahm, N., Bachmann, P., Debus, J. L., Haker, M.-C., Mashhadiakbar, P., Langhorst, S. E., Baldt, J., Streckenbach, B., Heidler, F., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.946351 · Cited by 29
Rahmanzadeh, R., Weigel, M., Lu, P., Melie‐García, L., Nguyen, T. D., Cagol, A., Rosa, F. L., Baraković, M., Lutti, A., Wang, Y., et al. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2022.103177 · Cited by 29
Self-citationThe Multiple Sclerosis Modulatory Potential of Natural Multi-Targeting Antioxidants
Theodosis‐Nobelos, P., & Rekka, E. A. (2022) · Molecules · doi:10.3390/molecules27238402 · Cited by 27
Sen, M. K., Hossain, M. J., Mahns, D. A., & Brew, B. J. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11507-y · Cited by 29
A future of AI-driven personalized care for people with multiple sclerosis
Praet, J., Anderhalten, L., Comi, G., Horáková, D., Ziemssen, T., Vermersch, P., Lukas, C., Leemput, K. V., Steppe, M., Aguilera, C., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1446748 · Cited by 28
Self-citationGiacalone, G., Clarelli, F., Osiceanu, A. M., Guaschino, C., Brambilla, P., Sorosina, M., Liberatore, G., Zauli, A., Esposito, F., Rodegher, M., et al. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458514564590 · Cited by 27
Volpe, G., Bernstock, J. D., Peruzzotti‐Jametti, L., & Pluchino, S. (2016) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2016.12.005 · Cited by 27
Efficiency of antibody therapy in demyelinating diseases
Akaishi, T., & Nakashima, I. (2017) · International Immunology · doi:10.1093/intimm/dxx037 · Cited by 27
Liu, S., Liu, X., Chen, S., Xiao, Y., & Zhuang, W. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188644 · Cited by 27
Diomede, F., Rajan, T. S., D’Aurora, M., Bramanti, P., Merciaro, I., Marchisio, M., Gatta, V., Mazzon, E., & Trubiani, O. (2017) · Stem Cells International · doi:10.1155/2017/1606125 · Cited by 27
Ocrelizumab: A New B-cell Therapy for Relapsing Remitting and Primary Progressive Multiple Sclerosis
Stahnke, A. M., & Holt, K. M. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017747635 · Cited by 28
Olfactory function and cognition in relapsing–remitting and secondary-progressive multiple sclerosis
Carotenuto, A., Costabile, T., Moccia, M., Falco, F., Scala, M. R., Russo, C. V., Saccà, F., Rosa, A. D., Lanzillo, R., & Morra, V. B. (2018) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2018.09.024 · Cited by 27
Kober, S. E., Pinter, D., Enzinger, C., Damulina, A., Duckstein, H., Fuchs, S., Neuper, C., & Wood, G. M. D. O. (2019) · Clinical Neurophysiology · doi:10.1016/j.clinph.2019.08.025 · Cited by 27
Apolipoproteins AI and E are associated with neuroaxonal injury to gray matter in multiple sclerosis
McComb, M., Parambi, R., Browne, R. W., Bodziak, M. L., Jakimovski, D., Bergsland, N., Maceski, A. M., Weinstock‐Guttman, B., Kühle, J., Zivadinov, R., et al. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102389 · Cited by 27
Cyclophosphamide treatment in active multiple sclerosis
Gómez‐Figueroa, E., Gutierrez-Lanz, E., Alvarado‐Bolaños, A., Vanegas, A. C., García‐Estrada, C., Zabala‐Ángeles, I., Cadena‐Fernández, A., Rivas‐Alonso, V., Irene, T.-F., & Flores-Rivera, J. D. J. (2021) · Neurological Sciences · doi:10.1007/s10072-021-05052-1 · Cited by 27
Primary progressive multiple sclerosis: current therapeutic strategies and future perspectives
Gajofatto, A., Turatti, M., & Benedetti, M. D. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1257385 · Cited by 27
Is there an effect of dietary intake on MS-related fatigue? – A systematic literature review
Pommerich, U. M., Brincks, J., & Christensen, M. E. (2018) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2018.08.017 · Cited by 26
Vermersch, P., Martinelli, V., Pfleger, C., Rieckmann, P., Alonso-Magdalena, L., Galazka, A. R., Dangond, F., & Phillips, L. D. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.12.015 · Cited by 26
Mehra, V., Rhone, E., Widya, S., Zuckerman, M. A., Potter, V. T., Raj, K. K., Kulasekararaj, A. G., McLornan, D. P., de Lavallade, H., Benson-Quarm, N., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz047 · Cited by 26
Metadata
- Authors
- Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., Bebo, B., Calabresi, P. A., Clanet, M., Comi, G., Fox, R. J., Freedman, M. S., Goodman, A. D., Inglese, M., Kappos, L., Kieseier, B. C., Lincoln, J. A., Lubetzki, C., Miller, A. E., Montalban, X., O'Connor, P. W., Petkau, J., Pozzilli, C., Rudick, R. A., Sormani, M. P., Stüve, O., Waubant, E., & Polman, C. H.
- Affiliations
- Cleveland Clinic (US)
- From the Corinne Goldsmith Dickenson Center for Multiple Sclerosis (F.D.L., A.E.M.), Icahn School of Medicine at Mount Sinai, New York, NY; Scientific and Clinical Review Associates, LLC (S.C.R.), Salisbury, CT; The Mellen Center for MS Treatment and Research (J.A.C., R.J.F., R.A.R.), Cleveland Clinic, OH; the Department of Biostatistics (G.R.C.), University of Alabama at Birmingham; the Danish Multiple Sclerosis Center (P.S.S.), Department of Neurology, Copenhagen University Hospital Rigshospitalet...
- Corresponding author
- Lublin, Fred D.
- ORCID
- Lublin, Fred D.
- Reingold, Stephen C.
- Cohen, Jeffrey A.
- Cutter, Gary R.
- Sørensen, Per Soelberg
- Thompson, Alan J.
- Wolinsky, Jerry S.
- Balcer, Laura J.
- Banwell, Brenda
- Barkhof, Frederik
- Bebo, Bruce
- Calabresi, Peter A.
- Comi, Giancarlo
- Fox, Robert J.
- Goodman, Andrew D.
- Inglese, Matilde
- Kappos, Ludwig
- Lincoln, John A.
- Lubetzki, Catherine
- Miller, Aaron E.
- O'Connor, Paul W.
- Pozzilli, Carlo
- Rudick, Richard A.
- Sormani, Maria Pia
- Stüve, Olaf
- Waubant, Emmanuelle
- Polman, Chris H.
- Venue
- Neurology
- Published
- 2014-07-15
- Volume
- 83
- Issue
- 3
- Pages
- 278-286
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC4117366
- OpenAlex
- W2105206040
- Cited by
- 3,177
- References
- 32
- Citations by year
- 2026: 229 · 2025: 266 · 2024: 335 · 2023: 308 · 2022: 333 · 2021: 333 · 2020: 298 · 2019: 274 · 2018: 232 · 2017: 236 · 2016: 193 · 2015: 105 · 2014: 27
- FWCI
- 139.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Neurology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- National Multiple Sclerosis Society
- Eli Lilly and Company
- Pfizer
- Amylin Pharmaceuticals
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Teva Pharmaceutical Industries
- Alexion Pharmaceuticals
- Celgene
- F. Hoffmann-La Roche
- Cleveland Clinic
- Novartis Pharmaceuticals Corporation
- University of Alabama at Birmingham
- European Committee for Treatment and Research in Multiple Sclerosis
- Wellcome Trust
- Ironwood Pharmaceuticals, Incorporated
- University of Alabama
- Myelin Repair Foundation
- University of Texas Health Science Center at Houston
- GW Pharmaceuticals
- Acorda Therapeutics
- Prothena
- Glenmark Pharmaceuticals
- National Institute for Health and Care Research
- Multiple Sclerosis Society
- University of Cambridge
- European Commission
- Bayer HealthCare
- Wolfson Foundation
- National Research Foundation
- Eisai
- Multiple Sclerosis International Federation
- Schweizerische Multiple Sklerose Gesellschaft
- Sun Pharma
- Serono Symposia International Foundation
- Grifols
- National Institutes of Health
- Genentech
- EMD Serono
- Bayer Canada
- Sanofi Genzyme
- Canadian Institutes of Health Research
- Natural Sciences and Engineering Research Council of Canada
- Medical Research Council
- National Heart, Lung, and Blood Institute
- National Institute of Neurological Disorders and Stroke
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
- Keywords
- multiple sclerosis, clinical course, disease phenotypes, clinical trial design, relapse rate, disease activity, disease progression, MRI findings, biomarkers
- MeSH terms
- Clinical Trials as Topic, Humans, Multiple Sclerosis, Societies, Medical, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
